A diary of the thought process behind my investment decisions
Just What The Market Needs
If Sanofi does indeed take over Genzyme that should give a nice boost to the market. The deal would be worth close to $20 billion in cash. A large chunk of that cash should find its way into other biotechnology stocks. In my opinion Gilead is a screaming buy right here, given their buyback and this possible takeover.